# US 5,708,035 A · Methods of use and compositions of R(-) fluoxetine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,708,035 A
- Document ID: US5708035A
- Status: Granted
- Kind: A
- Application number: 08/446,348
- Filed: 1995-05-22
- Granted: 1998-01-13
- Earliest claimed: 1991-02-04
- Assignees: Sepracor Inc.; The McLean Hospital Corporation
- Inventors: James W. Young; Timothy J. Barberich; Martin H. Teicher
- Web page: https://patentgrep.com/patent/US5708035A

## CPC

- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method and composition are disclosed utilizing the pure R(-) isomer of fluoxetine which is a potent antidepressant and appetite suppressant substantially free of adverse effects. In addition, a method and composition are disclosed utilizing the pure R(-) isomer of fluoxetine which is useful to treat migraine headaches, pain, in particular chronic pain, psychoactive substance abuse disorders and obsessive compulsive disorders.

## Claims

### Claim 1

A method of eliciting an antidepressant effect in a human which comprises administering to said human in need of antidepressant therapy an effective amount of R(-) fluoxetine, or a pharmaceutically acceptable salt thereof, substantially free of its S(+) stereoisomer.

### Claim 2 (depends on 1)

The method of claim 1 wherein the amount administered is about 1 mg to about 100 mg per day.

### Claim 3 (depends on 2)

The method according to claim 2 wherein the amount administered is about 5 mg to about 60 mg per day.

### Claim 4 (depends on 1)

The method according to claim 1 wherein the amount of R(-) fluoxetine or a pharmaceutically acceptable salt thereof is greater than approximately 99% by weight.

### Claim 5 (depends on 1)

The method according to claim 1 wherein R(-) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its S(+) stereoisomer is administered together with a pharmaceutically acceptable carrier.

### Claim 6 (depends on 2, 3)

A method according to claim 2 or 3 wherein R(-) fluoxetine hydrochloride is administered.

### Claim 7

A method of suppressing appetite in a human which comprises administering to said human in need of appetite suppression an effective amount of R(-) fluoxetine, or a pharmaceutically acceptable salt thereof, substantially free of its S(+) stereoisomer.

### Claim 8 (depends on 7)

The method of claim 7 wherein the amount administered is about 1 mg to about 100 mg per day.

### Claim 9 (depends on 8)

The method according to claim 8 wherein the amount administered is about 5 mg to about 60 mg per day.

### Claim 10 (depends on 7)

The method according to claim 7 wherein the amount of R(-) fluoxetine or a pharmaceutically acceptable salt thereof is greater than approximately 99% by weight.

### Claim 11 (depends on 7)

The method according to claim 7 wherein R(-) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its S(+) stereoisomer is administered together with a pharmaceutically acceptable carrier.

### Claim 12 (depends on 8, 9)

A method according to claim 8 or 9 wherein R(-) fluoxetine hydrochloride is administered.

### Claim 13

A method of treating pain in a human comprising administering to said human in need of such treatment an effective amount of R(-) fluoxetine, or a pharmaceutically acceptable salt thereof, substantially free of its S(+) stereoisomer.

### Claim 14 (depends on 13)

The method of claim 13 wherein the amount administered is about 1 mg to about 100 mg per day.

### Claim 15 (depends on 14)

The method according to claim 14 wherein the amount administered is about 5 mg to about 60 mg per day.

### Claim 16 (depends on 13)

The method according to claim 13 wherein the amount of R(-) fluoxetine or a pharmaceutically acceptable salt thereof is greater than approximately 99% by weight.

### Claim 17 (depends on 13)

The method according to claim 13 wherein R(-) fluoxetine or a pharmaceutically acceptable salt thereof, substantially free of its S(+) stereoisomer is administered together with a pharmaceutically acceptable carrier.

### Claim 18 (depends on 14, 15)

A method according to claim 14 or 15 wherein R(-) fluoxetine hydrochloride is administered.

### Claim 19

A method of treating at least one psychoactive substance use disorder in a human which comprises administering an effective amount of R(-) fluoxetine, or a pharmaceutically acceptable salt thereof, substantially free of its S(+) stereoisomer.

### Claim 20

A method of treating at least one obsessive compulsive disorder in a human which comprises administering an effective amount of R(-) fluoxetine, or a pharmaceutically acceptable salt thereof, substantially free of its S(+) stereoisomer.